Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"
- PMID: 36794938
- PMCID: PMC10019158
- DOI: 10.1128/aac.00326-22
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"
Erratum for
-
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694877 Free PMC article. Clinical Trial.
Similar articles
-
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164321. doi: 10.1128/AAC.01643-21. Epub 2021 Oct 25. Antimicrob Agents Chemother. 2022. PMID: 34694877 Free PMC article. Clinical Trial.
-
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.AIDS Res Hum Retroviruses. 2018 Apr;34(4):343-346. doi: 10.1089/AID.2017.0184. Epub 2018 Mar 22. AIDS Res Hum Retroviruses. 2018. PMID: 29444582 Free PMC article.
-
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4. Lancet Infect Dis. 2019. PMID: 30732940 Clinical Trial.
-
Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.Ann Pharmacother. 2014 Mar;48(3):395-403. doi: 10.1177/1060028013513558. Epub 2013 Nov 19. Ann Pharmacother. 2014. PMID: 24259658 Review.
-
[Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials].Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:26-30. doi: 10.1016/S0213-005X(15)30006-9. Enferm Infecc Microbiol Clin. 2015. PMID: 25858609 Review. Spanish.
Publication types
LinkOut - more resources
Full Text Sources